Document is current
Any future updates will be listed below
-
Authors
Vercellino, Justin
Małachowska, Beata
Kulkarni, Shilpa
Bell, Brett I.
Shajahan, Shahin
Shinoda, Kosaku
Eichenbaum, Gary
Verma, Amit K.
Ghosh, Sanchita P.
Yang, Weng-Lang
Frenette, Paul S.
Guha, Chandan http://orcid.org/0000-0002-1906-2186
-
Funding
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (U01AI133608)
- License Information
-
More Information
Article History
Received: 9 February 2024
Accepted: 16 April 2024
First Online: 29 April 2024
Declarations
:
: The animal study protocol used for this study is entitled “Develop mitigation strategies for radiation induced vascular injuries,” and was under protocol number 00001992 which was initially approved on November 11, 2019. All animal experiments and procedures were performed in accordance with protocols approved from the Institutional Animal Care and Use Committee at the Albert Einstein College of Medicine. Animal care and all experimental procedures were conducted in accordance with the Animal Research: Reporting of In Vivo Experiments (ARRIVE) 2.0 guidelines.
: G.E. was an employee of Janssen Pharmaceuticals and worked on the development of thrombopoietin mimetic (JNJ-26366821). J.V., W.Y., G.E., and C.G. have patented TPOm under US20230104658A1. G.E. and C.G. are co-founders of Bio Convergent Health. All other authors declare no competing interests.
